CAT Management Changes

Cambridge Antibody Tech Group PLC
21 December 2000


For further information contact:

Cambridge Antibody Technology        
Tel: [phone]
David Chiswell, CEO
John Aston, Finance Director       
Rowena Gardner, Head of Corporate Communications       

HCC De Facto (Europe)
Tel: [phone]
Adam Michael
                                                                              
BMC Communications/The Trout Group (USA)
Tel: [phone]
Brad Miles, ext.17 (media)
Brandon Lewis, ext.15 (investors)


CAMBRIDGE ANTIBODY TECHNOLOGY ANNOUNCES MANAGEMENT CHANGES 

Melbourn, UK  Cambridge Antibody Technology (LSE: CAT) is pleased to announce
changes designed to put the management structure and the key managers in place
to cover the next phase of CAT's growth.

As CAT has grown, so the range of activities covered by its Research
Department has become increasingly diverse, encompassing technology
development, responsibility for our contractual obligations to partners,
development of clinical antibody candidates and scientific support functions.
We have decided that these functions can be better managed by focussing on
smaller units. 

David Chiswell, CAT's CEO, commented 'The generation of CAT's own therapeutic
antibody clinical portfolio, alongside those products which are being
developed by our partners, is key to our future success. The management
structure of the company is being developed to meet these needs and to exploit
the opportunities available to CAT. In addition, it is important that CAT's
employees are allowed and encouraged to develop and assume greater
responsibility.'

Jason Avery, Nigel Burns and Diane Mellett have been promoted to Senior Vice
President (SVP). Jason becomes SVP Business Alliances, Nigel becomes SVP
Pre-Clinical and Diane becomes General Counsel. In addition, three individuals
have been promoted to Vice President (VP). Alex Duncan becomes VP Drug
Discovery, Jon Green becomes VP Operations and Duncan Casson becomes VP
Project Management.

Kevin Johnson, currently CAT's Research Director, takes on the new role of
Chief Technology Officer and will head the Technology Department that will
expand CAT's efforts in the further exploitation and development of its
antibody technology platform. 


Notes to Editors:

Cambridge Antibody Technology (LSE: CAT) 
CAT is a UK biotechnology company using its proprietary technologies in human
monoclonal antibodies for drug discovery and drug development.  Based in
Melbourn, 10 miles south of Cambridge, England, CAT currently employs nearly
200 people.  
CAT is listed on the London Stock Exchange, having raised £41m in its IPO in
March 1997. A secondary offering in March 2000 raised £93m.  
CAT has a world-leading platform technology for rapidly isolating fully human
monoclonal antibodies using phage display systems.  CAT has an extensive phage
display antibody library, currently incorporating around 100 billion distinct
antibodies. This library forms the basis for the company's strategy to develop
a portfolio of clinical development programs and for discovering new drug
leads using functional genomics.  Four fully human therapeutic antibodies
developed by CAT are at various stages of clinical trials.  
CAT works in partnership with other companies at all stages of the drug
discovery and development process. CAT's collaborations, past and present,
include: AstraZeneca, BASF Pharma, Eli Lilly, Genentech, Genetics Institute,
Genzyme, Human Genome Sciences, Immunex, Oxford GlycoSciences, Pharmacia
Corporation, Pfizer, Wyeth-Ayerst and Zyomyx.